
Patients with non-small-cell lung cancer (NSCLC) often present with metastatic disease, have a poor prognosis, and are leading cancer-related deaths worldwide. Life expectancy with palliative chemotherapy alone does not exceed one-and-a half years. Recently, the development of immune checkpoint inhibitors (ICI) has facilitated long-term disease control in about 20–30 % of metastatic NSCLC and median
Like
Save
Share